Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of HMPL-523 in Patients With Relapsed or Refractory Hematologic Malignancies

NCT02503033 is registered in ClinicalTrials.gov with Hutchison Medipharma Limited as lead sponsor.

NCT NCT02503033
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02503033 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of HMPL-523 in Patients With Relapsed or Refractory Hematologic Malignancies
Lead sponsor
Hutchison Medipharma Limited
Phase
Phase 1
Overall status
Unknown status
Start date
November 30, 2015
Completion date
March 31, 2021
Enrollment
78 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

hematologic malignancies